Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Management Changes: Calidi Biotherapeutics has strengthened its leadership team by appointing Eric Poma, PhD, as CEO and Guy Travis Clifton, MD, as Chief Medical Officer, both bringing extensive biopharmaceutical experience to the company.
Clinical Developments: The FDA has cleared Calidi's IND application for CLD-201, an innovative stem cell-based immunotherapy targeting solid tumors, while the company is advancing its Redtail platform with IL15-superagonist as a key payload for tumor treatment.
Trade with 70% Backtested Accuracy
Analyst Views on CLDI
About CLDI
About the author
Calidi Biotherapeutics Announces Financial Results and Key Operational Updates for Q3 2025
New Data Presentation: Calidi Biotherapeutics presented promising preclinical data on CLD-401 at the SITC annual meeting, showing its ability to evade immune clearance and effectively deliver genetic medicines to metastatic tumor sites.
Scientific Advisory Board Established: The company formed a new Scientific Advisory Board comprising esteemed experts to support the development of CLD-401 and enhance the capabilities of its RedTail platform for targeted genetic medicine delivery.
Financial Update: Calidi raised $6.9 million through a public offering, increasing total gross proceeds for 2025 to $23 million, while reporting a net loss of $5.2 million for Q3 2025, slightly higher than the previous year.
Platform Expansion: The RedTail platform's functionality is being expanded with new payloads and programmable membrane targeting, advancing its applications in virotherapy beyond oncology.
Calidi Biotherapeutics Completes $6.9 Million Public Offering with Full Over-Allotment Option Exercised by Underwriters
Public Offering Announcement: Calidi Biotherapeutics has successfully closed an underwritten public offering, raising $6.9 million in gross proceeds, including the full exercise of the underwriters' over-allotment option.
Details of Securities Sold: The offering included 1,922,764 common stock units and 1,528,000 pre-funded warrant units, with prices set at $2.00 per Common Stock Unit and $1.999 per Pre-Funded Unit.
Company Overview: Calidi Biotherapeutics is focused on developing targeted therapies for cancer treatment, utilizing its proprietary Redtail platform to deliver genetic medicines to metastatic sites.
Forward-Looking Statements: The press release contains forward-looking statements regarding the company's future developments and potential risks associated with clinical trials and capital raising efforts.
Nasdaq Declines 1%; Lowe's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks declined mid-session, with the Nasdaq Composite dropping over 200 points and the S&P 500 and Dow also experiencing losses.
Lowe's Earnings Report: Lowe's Companies reported better-than-expected second-quarter earnings, with adjusted EPS rising to $4.33 and quarterly sales reaching $23.96 billion, prompting an update in fiscal guidance.
Equities Movement: NovaBay Pharmaceuticals saw a significant stock increase of 68% after a securities purchase agreement, while enVVeno Medical Corporation shares plummeted 72% following FDA news.
Global Market Trends: European shares showed mixed results, Asian markets closed mixed with Japan's Nikkei falling, and U.S. mortgage applications decreased by 1.4% from the previous week.
Dow Rises by 100 Points; Target Stock Declines Following Q2 Earnings Report
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones gaining over 100 points, while NASDAQ and S&P 500 experienced declines.
Target Corporation Earnings Report: Target's shares fell about 9% despite reporting adjusted earnings per share of $2.05, beating estimates, but sales declined year-over-year.
Notable Stock Movements: NovaBay Pharmaceuticals saw a significant increase of 104% after a securities purchase agreement, while enVVeno Medical Corp dropped 70% due to FDA non-approval.
Global Market Trends: European and Asian markets closed mixed, with varying performances across major indices, and U.S. mortgage applications decreased by 1.4%.
Calidi Biotherapeutics Reveals Pricing for $6 Million Underwritten Public Offering
Public Offering Announcement: Calidi Biotherapeutics has announced a public offering priced at $6 million, consisting of common stock and pre-funded warrant units, despite challenging market conditions.
Details of the Offering: The offering includes 1,472,764 common stock units priced at $2.00 each and 1,528,000 pre-funded warrant units priced at $1.999 each, with warrants exercisable for five years.
Underwriters and Closing Date: Ladenburg Thalmann & Co. Inc. is the sole book-running manager, and the offering is expected to close on August 21, 2025, pending customary closing conditions.
Company Overview: Calidi Biotherapeutics focuses on developing targeted therapies using its proprietary Redtail platform for treating cancers such as non-small cell lung cancer and ovarian cancer.
Calidi Loss Down 23 Percent in Fiscal Q2
Financial Performance: Calidi Biotherapeutics reported a GAAP earnings per share of $(1.99) for Q2 2025, missing analyst estimates by $0.07, with a net loss of $5.7 million, an improvement from $7.4 million in the previous year, but cash reserves decreased significantly to $5.3 million.
Product Development and Strategy: The company is advancing its cancer therapy platforms, particularly the RedTail enveloped virus system and allogeneic stem cell-based immunotherapy, while facing ongoing funding challenges and aiming for key regulatory milestones, including an IND filing for CLD-401 by the end of 2026.
Calidi Biotherapeutics Announces Financial Results and Key Operational Updates for Q3 2025
New Data Presentation: Calidi Biotherapeutics presented promising preclinical data on CLD-401 at the SITC annual meeting, showing its ability to evade immune clearance and effectively deliver genetic medicines to metastatic tumor sites.
Scientific Advisory Board Established: The company formed a new Scientific Advisory Board comprising esteemed experts to support the development of CLD-401 and enhance the capabilities of its RedTail platform for targeted genetic medicine delivery.
Financial Update: Calidi raised $6.9 million through a public offering, increasing total gross proceeds for 2025 to $23 million, while reporting a net loss of $5.2 million for Q3 2025, slightly higher than the previous year.
Platform Expansion: The RedTail platform's functionality is being expanded with new payloads and programmable membrane targeting, advancing its applications in virotherapy beyond oncology.
Calidi Biotherapeutics Completes $6.9 Million Public Offering with Full Over-Allotment Option Exercised by Underwriters
Public Offering Announcement: Calidi Biotherapeutics has successfully closed an underwritten public offering, raising $6.9 million in gross proceeds, including the full exercise of the underwriters' over-allotment option.
Details of Securities Sold: The offering included 1,922,764 common stock units and 1,528,000 pre-funded warrant units, with prices set at $2.00 per Common Stock Unit and $1.999 per Pre-Funded Unit.
Company Overview: Calidi Biotherapeutics is focused on developing targeted therapies for cancer treatment, utilizing its proprietary Redtail platform to deliver genetic medicines to metastatic sites.
Forward-Looking Statements: The press release contains forward-looking statements regarding the company's future developments and potential risks associated with clinical trials and capital raising efforts.
Nasdaq Declines 1%; Lowe's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks declined mid-session, with the Nasdaq Composite dropping over 200 points and the S&P 500 and Dow also experiencing losses.
Lowe's Earnings Report: Lowe's Companies reported better-than-expected second-quarter earnings, with adjusted EPS rising to $4.33 and quarterly sales reaching $23.96 billion, prompting an update in fiscal guidance.
Equities Movement: NovaBay Pharmaceuticals saw a significant stock increase of 68% after a securities purchase agreement, while enVVeno Medical Corporation shares plummeted 72% following FDA news.
Global Market Trends: European shares showed mixed results, Asian markets closed mixed with Japan's Nikkei falling, and U.S. mortgage applications decreased by 1.4% from the previous week.
Dow Rises by 100 Points; Target Stock Declines Following Q2 Earnings Report
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones gaining over 100 points, while NASDAQ and S&P 500 experienced declines.
Target Corporation Earnings Report: Target's shares fell about 9% despite reporting adjusted earnings per share of $2.05, beating estimates, but sales declined year-over-year.
Notable Stock Movements: NovaBay Pharmaceuticals saw a significant increase of 104% after a securities purchase agreement, while enVVeno Medical Corp dropped 70% due to FDA non-approval.
Global Market Trends: European and Asian markets closed mixed, with varying performances across major indices, and U.S. mortgage applications decreased by 1.4%.
Calidi Biotherapeutics Reveals Pricing for $6 Million Underwritten Public Offering
Public Offering Announcement: Calidi Biotherapeutics has announced a public offering priced at $6 million, consisting of common stock and pre-funded warrant units, despite challenging market conditions.
Details of the Offering: The offering includes 1,472,764 common stock units priced at $2.00 each and 1,528,000 pre-funded warrant units priced at $1.999 each, with warrants exercisable for five years.
Underwriters and Closing Date: Ladenburg Thalmann & Co. Inc. is the sole book-running manager, and the offering is expected to close on August 21, 2025, pending customary closing conditions.
Company Overview: Calidi Biotherapeutics focuses on developing targeted therapies using its proprietary Redtail platform for treating cancers such as non-small cell lung cancer and ovarian cancer.
Calidi Loss Down 23 Percent in Fiscal Q2
Financial Performance: Calidi Biotherapeutics reported a GAAP earnings per share of $(1.99) for Q2 2025, missing analyst estimates by $0.07, with a net loss of $5.7 million, an improvement from $7.4 million in the previous year, but cash reserves decreased significantly to $5.3 million.
Product Development and Strategy: The company is advancing its cancer therapy platforms, particularly the RedTail enveloped virus system and allogeneic stem cell-based immunotherapy, while facing ongoing funding challenges and aiming for key regulatory milestones, including an IND filing for CLD-401 by the end of 2026.
